Cangrelor Steps Up to 'Platelet,' Hits Phase III Data Home Run
Bolstering its news in January, when the firm disclosed that the intravenous antiplatelet cangrelor had proven strong in a Phase III trial as compared to oral clopidogrel, The Medicine Co.'s scientific team offered specifics over the weekend at the American College of Cardiology Scientific Session in San Francisco.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST